aTYR PHARMA (ATYR) Cash from Operations (2014 - 2026)
aTYR PHARMA's (ATYR) quarterly Cash from Operations came in at 12517000.0 in Q1 2026, up 18.83% YoY from 10533872.18 in Q1 2025, and down 2.63% on a QoQ basis from 12196000.0 in Q4 2025.
aTYR PHARMA (ATYR) Cash from Operations (2014 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 13 years of Cash from Operations data on file, last reported at 12517000.0 in Q1 2026.
- Quarterly Cash from Operations rose 18.83% year-over-year to 12517000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 59083000.0 (up 4.95% YoY) and the FY2025 annual result came in at 61986000.0, up 10.32% from the prior year.
- Cash from Operations slipped to 12517000.0 in Q1 2026, from 12196000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 590000.0 in Q1 2023 to a low of 22380000.0 in Q1 2024.
- A 5-year average of 12866411.76 and a median of 12281000.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2023 — Cash from Operations jumped 94.17% — and 2024, when it sank 3693.22%.
- Tracing ATYR's Cash from Operations over 5 years: stood at 10369000.0 in 2022, then declined by 6.68% to 11062000.0 in 2023, then decreased by 18.71% to 13132000.0 in 2024, then grew by 7.13% to 12196000.0 in 2025, then decreased by 2.63% to 12517000.0 in 2026.
- The last three Cash from Operations figures came in at 12517000.0 (Q1 2026), 12196000.0 (Q4 2025), and 20476000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | aTYR PHARMA | 49.54 Mn | -7.87 Mn | - | -9.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.35 Mn |
| Jun 30, 2026 | -9.35 Mn |
| Mar 31, 2026 | -12.52 Mn |
| Mar 31, 2026 | -12.52 Mn |
| Dec 31, 2025 | -12.20 Mn |
| Dec 31, 2025 | -12.20 Mn |
| Sep 30, 2025 | -20.48 Mn |
| Sep 30, 2025 | -20.48 Mn |
| Jun 30, 2025 | -13.89 Mn |
| Jun 30, 2025 | -13.89 Mn |
| Mar 31, 2025 | -15.42 Mn |
| Mar 31, 2025 | -15.42 Mn |
| Dec 31, 2024 | -13.13 Mn |
| Dec 31, 2024 | -13.13 Mn |
| Sep 30, 2024 | -13.16 Mn |
| Sep 30, 2024 | -13.16 Mn |
| Jun 30, 2024 | -20.45 Mn |
| Jun 30, 2024 | -20.45 Mn |
| Mar 31, 2024 | -22.38 Mn |
| Mar 31, 2024 | -22.38 Mn |